128 related articles for article (PubMed ID: 3262151)
1. Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens.
Wiebke EA; Rosenberg SA; Lotze MT
J Clin Oncol; 1988 Sep; 6(9):1440-9. PubMed ID: 3262151
[TBL] [Abstract][Full Text] [Related]
2. Adoptive immunotherapy with IL-2 results in the loss of delayed-type hypersensitivity responses and the development of immediate hypersensitivity to recall antigens.
Kradin RL; Kurnick JT; Preffer FI; Dubinett SM; Dickersin GR; Pinto C
Clin Immunol Immunopathol; 1989 Feb; 50(2):184-95. PubMed ID: 2783665
[TBL] [Abstract][Full Text] [Related]
3. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
[TBL] [Abstract][Full Text] [Related]
4. Enhancement by interleukin 4 of interleukin 2- or antibody-induced proliferation of lymphocytes from interleukin 2-treated cancer patients.
Treisman J; Higuchi CM; Thompson JA; Gillis S; Lindgren CG; Kern DE; Ridell SR; Greenberg PD; Fefer A
Cancer Res; 1990 Feb; 50(4):1160-4. PubMed ID: 2153452
[TBL] [Abstract][Full Text] [Related]
5. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
[TBL] [Abstract][Full Text] [Related]
6. Immunologic effects of interleukin-2 adoptive immunotherapy in humans: acute in vitro anergy, in vivo antibody response to tetanus.
Ades EW; Bosse D; Orr S; Gillespie T
Pathobiology; 1990; 58(4):226-9. PubMed ID: 2252544
[TBL] [Abstract][Full Text] [Related]
7. Immune responses in humans while receiving adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells: acute anergy to mitogens and recall antigens.
Ades EW; Bosse D; Orr S; Gillespie T
Pathobiology; 1990; 58(2):78-83. PubMed ID: 2360981
[TBL] [Abstract][Full Text] [Related]
8. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
9. Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.
Sosman JA; Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; O'Boyle K; Fisher RI; Boldt DH; Doroshow J
J Clin Oncol; 1993 Aug; 11(8):1496-505. PubMed ID: 8336188
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic human liposomal melanoma vaccine with or without IL-2 in metastatic melanoma patients: clinical and immunobiological effects.
Adler A; Schachter J; Barenholz Y; Bar LK; Klein T; Korytnaya R; Sulkes A; Michowiz R; Cohen Y; Kedar I
Cancer Biother; 1995; 10(4):293-306. PubMed ID: 8590895
[TBL] [Abstract][Full Text] [Related]
11. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract][Full Text] [Related]
12. Autologous B lymphoblastoid cell lines and long-term cultured T cells as stimulators in the mixed lymphocyte reaction: analysis of the role of HLA class II antigens as stimulatory molecules.
Santoli D; Radka SF; Igarashi M; Kreider BL; Ferrone S
J Immunol; 1986 Jul; 137(2):400-7. PubMed ID: 2941479
[TBL] [Abstract][Full Text] [Related]
13. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
[TBL] [Abstract][Full Text] [Related]
14. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response.
Barth A; Hoon DS; Foshag LJ; Nizze JA; Famatiga E; Okun E; Morton DL
Cancer Res; 1994 Jul; 54(13):3342-5. PubMed ID: 8012946
[TBL] [Abstract][Full Text] [Related]
15. Efficient harvest of in vivo IL-2-activated CD3+ lymphocytes for adoptive immunotherapy by selective leukapheresis (lymphocytapheresis).
Masucci G; Svensson A; Hansson M; Hansson J; Nakazawa T; Salazar F; Petersson M; Kiessling R
J Hematother; 1997 Jun; 6(3):253-60. PubMed ID: 9234180
[TBL] [Abstract][Full Text] [Related]
16. Gender differences in response to the multitest CMI skin test in the general population.
Vine MF; Stein L; Weigle K
Ann Allergy Asthma Immunol; 2000 Apr; 84(4):445-50. PubMed ID: 10795654
[TBL] [Abstract][Full Text] [Related]
17. Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma.
Favrot MC; Combaret V; Negrier S; Philip I; Thiesse P; Freydel C; Bijmann JT; Franks CR; Mercatello A; Philip T
J Biol Response Mod; 1990 Apr; 9(2):167-77. PubMed ID: 1971303
[TBL] [Abstract][Full Text] [Related]
18. Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104).
Asemissen AM; Scheibenbogen C; Letsch A; Hellstrand K; Thorén F; Gehlsen K; Schmittel A; Thiel E; Keilholz U
Clin Cancer Res; 2005 Jan; 11(1):290-7. PubMed ID: 15671558
[TBL] [Abstract][Full Text] [Related]
19. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization.
Disis ML; Schiffman K; Gooley TA; McNeel DG; Rinn K; Knutson KL
Clin Cancer Res; 2000 Apr; 6(4):1347-50. PubMed ID: 10778962
[TBL] [Abstract][Full Text] [Related]
20. Reduced alloreactive T-cell activation after alcohol intake is due to impaired monocyte accessory cell function and correlates with elevated IL-10, IL-13, and decreased IFNgamma levels.
Szabo G; Mandrekar P; Dolganiuc A; Catalano D; Kodys K
Alcohol Clin Exp Res; 2001 Dec; 25(12):1766-72. PubMed ID: 11781510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
